Severe Autoimmune Thrombocytopenic Purpura during Interferon-α Therapy for Chronic Myelogenous Leukemia

2004 ◽  
Vol 112 (4) ◽  
pp. 217-218 ◽  
Author(s):  
Kosei Arimura ◽  
Naomichi Arima ◽  
Hideo Ohtsubo ◽  
Kakushi Matsushita ◽  
Toshimasa Kukita ◽  
...  
1998 ◽  
Vol 100 (4) ◽  
pp. 204-206 ◽  
Author(s):  
Rita Rachmani ◽  
Abraham Avigdor ◽  
Mona Youkla ◽  
Pia Raanani ◽  
Moshe Zilber ◽  
...  

Blood ◽  
2002 ◽  
Vol 100 (8) ◽  
pp. 2926-2931 ◽  
Author(s):  
Ikuya Sakai ◽  
Kazuto Takeuchi ◽  
Hayato Yamauchi ◽  
Hirosi Narumi ◽  
Shigeru Fujita

Because suppressor of cytokine signaling (SOCS) proteins are negative regulators of cytokine-induced signaling, it has been hypothesized that aberrant SOCS expression confers resistance against cytokine therapy. This study reports on the constitutive expression of SOCS3 in most chronic myelogenous leukemia (CML) cell lines, which are resistant to treatment with interferon α (IFN-α). In contrast, the KT-1/A3 cell line, in which constitutive expression of SOCS3 is barely detectable, is sensitive to IFN-α treatment. Forced expression of SOCS3 in the KT-1/A3 cell line confers resistance to IFN-α treatment. Furthermore, most of the blast cells from patients in CML blast crisis, which are usually resistant to IFN-α therapy, showed constitutive expression of SOCS3. These findings indicate that constitutive SOCS3 expression affects the IFN-α sensitivity of CML cell lines and blast cells from patients with CML blast crisis.


1995 ◽  
Vol 48 (3) ◽  
pp. 211-212 ◽  
Author(s):  
Manabu Sotomatsu ◽  
Masafumi Shimoda ◽  
Chitose Ogawa ◽  
Akihiro Morikawa

1998 ◽  
Vol 7 (2) ◽  
pp. 105-109
Author(s):  
Toru Momoi ◽  
Chikahide Hori ◽  
Mitsuyoshi Okumura ◽  
Akira Yoshida ◽  
Rieko Tanaka ◽  
...  

2004 ◽  
Vol 153 (2) ◽  
pp. 133-143 ◽  
Author(s):  
Hideo Tanaka ◽  
Kimio Tanaka ◽  
Nobuo Oguma ◽  
Kinro Ito ◽  
Takuo Ito ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document